Breast cancer screening; cost-effective in practice?

Area of Science:

• Public Health
• Oncology
• Health Economics

Background:

• National breast screening programs aim to reduce breast cancer mortality.
• Expectations for the Dutch program suggest a 16% reduction, with benefits potentially including improved quality of life.
• Critics argue that the actual benefits of screening programs are often overstated.

Purpose of the Study:

• To evaluate the effectiveness and cost-effectiveness of national breast cancer screening programs.
• To compare outcomes across different countries and identify factors influencing program success.
• To emphasize the need for continuous quality control in large-scale screening initiatives.

Main Methods:

• Analysis of data from Swedish, UK, and Dutch breast screening trials.
• Estimation of mortality reduction at the population level.
• Cost-effectiveness analysis using computer modeling, considering factors like incidence, healthcare costs, and attendance rates.

Main Results:

• Swedish trials suggest up to a 19% reduction in breast cancer mortality; UK data shows a 20% reduction.
• Early results from the Dutch program are favorable and meet or exceed expectations.
• Cost-effectiveness ratios vary significantly by country, ranging from €2650 to €9650 per life-year gained.

Conclusions:

• While promising, the long-term impact of the Dutch breast screening program is yet to be determined.
• Breast cancer screening benefits must be weighed against the burden on women and healthcare systems.
• Uniform screening policies are challenging due to variations in national contexts; continuous quality monitoring is essential for national programs.